Full-Time

Associate Software Engineer 1

Posted on 7/29/2026

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$58.7k - $103.5k/yr

Vernon Hills, IL, USA

Hybrid

Hybrid role; on-site work in Mettawa, Illinois.

Category
Software Engineering (1)
Required Skills
SQL
Java
TypeScript
Data Analysis

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Bachelor’s degree in computer science or relevant field.
  • Strong programming skills in Java, SQL, and Typescript.
  • Comfortable working in a dynamic environment and developing flexible solutions to meet evolving requirements.
  • Ability to work independently with strong time management skills.
  • Excellent written and verbal communication skills, with ability to communicate effectively with scientists, developers, application analysts, managers and IT professionals.
  • Good presentation, training, and documentation skills.
Responsibilities
  • Independently design and develop software to answer scientific or business questions, demonstrating proficiency across a range of technologies related to programming languages, data integration, and data visualization and analysis.
  • Design, develop, and maintain back-end components of enterprise applications.
  • Ensure security and integrity of software solutions, safeguarding data and system operations.
  • Continuously seeks learning opportunities to stay updated with emerging web technologies and data analysis tools, applying innovative solutions to improve processes and outcomes.
  • Use AbbVie values to govern decisions, actions and behaviors, ensuring that work reflects our commitments to Patients, Affordability, Accountability & Service Commitment, Decisiveness, Innovation & Thoughtful Risk while fostering Diversity & Inclusion, Integrity & Respect, Learning, Continuous Improvement & Personal Growth, Teamwork & Collaboration.
Desired Qualifications
  • APEX development experience in Salesforce.
  • Experience with incorporating Generative AI techniques into custom software solutions

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Skyrizi and Rinvoq projected to exceed $27 billion in combined sales by 2027
  • FDA approval for pediatric Skyrizi treats 20,000 US children under ten with psoriasis annually
  • Phase 3 EPCORE FL-1 trial showed TEPKINLY reduced lymphoma progression or death risk by 79%

What critics are saying

  • Skyrizi growth decelerated from 31.9% to 29.2% YoY, risking investor de-rating of 123x P/E valuation
  • U.S. House probe into China trials alleging PLA ties could trigger sanctions and force abandonment of China trial pipeline
  • Emraclidine Phase II schizophrenia trial failure knocked stock 12% and expects $1.3B IPR&D charge trimming EPS by 71¢

What makes AbbVie unique

  • Skyrizi and Rinvoq form a leading IL-23 and JAK immunology franchise offsetting Humira's 39% decline
  • Maviret is the only EU-approved treatment for both acute and chronic hepatitis C virus infection
  • Boey is Health Canada's first rapid-onset serotype E botulinum neurotoxin for glabellar lines

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 4th, 2026
AbbVie Q2 revenue up 10% to $17B amid immunology gains, lowers profit guidance on Apogee acquisition

AbbVie reported second-quarter revenue of $16.99 billion, up 10.2% year-on-year and exceeding analyst expectations of $16.79 billion. Adjusted earnings per share of $3.65 also beat consensus estimates of $3.61. The pharmaceutical company's growth was driven by its immunology portfolio, particularly SKYRIZI and RINVOQ, and neuroscience products including Vraylar and Vialev. CEO Robert Michael noted each portfolio "delivered growth above 20%". However, AbbVie lowered its full-year adjusted earnings guidance to $13.97 per share at the midpoint, a 1.5% decrease. Management attributed the revision to anticipated dilution from the planned Apogee Therapeutics acquisition and increased research and development spending. The company faces ongoing biosimilar pressure on legacy products whilst pursuing regulatory approvals for new indications and preparing to launch Tevapadon for Parkinson's disease.

Yahoo Finance
Aug 3rd, 2026
AbbVie's $21.7B SKYRIZI bet: one drug to fuel a third of 2026 revenue

AbbVie expects SKYRIZI to generate $21.7 billion of its projected $67.6 billion in 2026 revenue, representing nearly one-third of total sales from a single medicine. The immunology drug sold $5.5 billion in Q2 2026, up 24% operationally, whilst the company's next largest product, RINVOQ, brought in $2.5 billion. The concentration becomes significant as other segments struggle. Oncology revenue fell 2.4% operationally to $1.6 billion, whilst aesthetics slipped 0.9% to $1.3 billion. Neuroscience grew roughly 20% to $3.2 billion. AbbVie's experience with HUMIRA illustrates the biosimilar risk. The former blockbuster fell 36% operationally to $756 million in Q2 2026 due to competition. However, SKYRIZI's US composition-of-matter patent doesn't expire until 2033, with additional patents extending into the mid-2030s. Shares trade at $250.94, up 37% over twelve months, valuing the company at $444 billion.

Yahoo Finance
Jul 31st, 2026
AbbVie raises full-year guidance by $300M on strength of Skyrizi, Rinvoq, and neuroscience growth

AbbVie reported strong second-quarter 2026 results, driven by over 20% growth in SKYRIZI, RINVOQ, and its neuroscience portfolio. The company raised its full-year revenue guidance by $300 million. Management expects RINVOQ to reach combined peak sales approaching $2 billion in vitiligo and alopecia areata, significantly above previous projections. The Parkinson's portfolio, including tevapadone, is forecast to exceed $5 billion in peak sales. AbbVie is acquiring Apogee Therapeutics to strengthen its immunology pipeline with long-acting biologics for the 2030s and beyond. The transaction is expected to close in the third quarter. HUMIRA sales declined 36.1% due to biosimilar competition, whilst IMBRUVICA faces pressure from Medicare pricing reforms. The company aims to achieve a net leverage ratio of 2 times within two to three years following the Apogee acquisition.

Yahoo Finance
Jul 31st, 2026
AbbVie beats Q2 forecasts but cuts 2026 guidance on $10.9B Apogee Therapeutics acquisition

AbbVie reported second-quarter results that exceeded expectations but reduced its full-year guidance due to a major acquisition. Net revenues climbed 10.2% to $16.99 billion, beating the $16.78 billion estimate. Adjusted diluted earnings reached $3.65 per share, surpassing the $3.60 consensus. The immunology segment grew 15.1% to $8.79 billion, with Skyrizi and Rinvoq each up around 24%. Humira revenues fell 35.9% to $756 million. Neuroscience revenues rose 20.3% to $3.23 billion, whilst oncology declined 1.5% to $1.65 billion. AbbVie lowered its 2026 adjusted earnings per share guidance to a range of $13.87 to $14.07, down $0.04 at the midpoint. The reduction reflects $0.14 per share dilution from the proposed $10.9 billion acquisition of Apogee Therapeutics, expected to close in the third quarter.

Yahoo Finance
Jul 31st, 2026
AbbVie beats Q2 revenue expectations with $16.99B, up 10.2% year-on-year

AbbVie reported second-quarter revenue of $16.99 billion, beating analyst estimates of $16.79 billion and marking 10.2% year-on-year growth. The pharmaceutical company's non-GAAP earnings of $3.65 per share also exceeded expectations by 1.2%. Operating margin improved to 37.9%, up from 31.7% in the same quarter last year. However, management lowered full-year adjusted EPS guidance to $13.97 at the midpoint, a 1.5% decrease. Over the past two years, AbbVie's revenue has grown at an 8.2% annualised rate. Analysts expect revenue to grow 8.5% over the next 12 months. AbbVie, which spun off from Abbott Laboratories in 2013, develops medications for autoimmune diseases, cancer, and neurological disorders.